Market Research

Bioengineered Protein Drugs Market (Disease Condition: Cancer, Diabetes, Autoimmune Disorder, Infectious Disease, Hematopoiesis, CVD, Neurodegenerative, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2024-2034

Best Price Guarantee Length Publisher Published Date SKU
from $5,795 202 Pages Transparency Market Research Pvt. Ltd. April, 2024 TNPR18827842
Best Price Guarantee
Price from $5,795
Length 202 Pages
Publisher Transparency Market Research Pvt. Ltd.
Published Date April, 2024
SKU TNPR18827842

Bioengineered Protein Drugs Market (Disease Condition: Cancer, Diabetes, Autoimmune Disorder, Infectious Disease, Hematopoiesis, CVD, Neurodegenerative, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2024-2034


Bioengineered Protein Drugs Market – Scope of Report

TMR’s report on the global bioengineered protein drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global bioengineered protein drugs market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global bioengineered protein drugs market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the bioengineered protein drugs market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global bioengineered protein drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global bioengineered protein drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global bioengineered protein drugs market.

The report delves into the competitive landscape of the global bioengineered protein drugs market. Key players operating in the global bioengineered protein drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global bioengineered protein drugs market profiled in this report.

Key Questions Answered in Global bioengineered protein drugs Market Report
  • What is the sales/revenue generated by bioengineered protein drugs across all regions during the forecast period?
  • What are the opportunities in the global bioengineered protein drugs market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?
Bioengineered Protein Drugs Market – Research Objectives and Research Approach

The comprehensive report on the global bioengineered protein drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global bioengineered protein drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global bioengineered protein drugs market.


1. Preface
  1.1. Market Definition and Scope
  1.2. Market Segmentation
  1.3. Key Research Objectives
  1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Bioengineered Protein Drugs Market
4. Market Overview
  4.1. Introduction
  4.1.1. Product Definition
  4.1.2. Industry Evolution/Developments
  4.2. Overview
  4.3. Market Dynamics
  4.3.1. Drivers
  4.3.2. Restraints
  4.3.3. Opportunities
  4.4. Bioengineered Protein Drugs Market Analysis and Forecast, 2020-2034
5. Key Insights
  5.1. Pipeline Analysis
  5.2. Key Product /Brand Analysis
  5.3. Key Mergers & Acquisitions
  5.4. COVID-19 Pandemic Impact on Industry
6. Global Bioengineered Protein Drugs Market Analysis and Forecast, by Drug Type
  6.1. Introduction & Definition
  6.2. Key Findings/Developments
  6.3. Market Value Forecast, by Drug Type, 2020-2034
  6.3.1. Monoclonal Antibodies
  6.3.1.1. Humira
  6.3.1.2. Rituxan
  6.3.1.3. Avastin
  6.3.1.4. Herceptin
  6.3.1.5. Remicade
  6.3.1.6. Lucentis
  6.3.1.7. Enbrel
  6.3.1.8. Synazis
  6.3.1.9. Others
  6.3.2. Therapeutic Proteins
  6.3.2.1. Hormones
  6.3.2.2. Cytokines
  6.3.2.2.1. Neupogen
  6.3.2.2.2. Neulasta
  6.3.2.2.3. Interferon Alpha
  6.3.2.2.4. Erythropoietin Alpha
  6.3.2.2.5. Interleukin
  6.3.2.2.6. Others
  6.3.3. Blood Factor
  6.3.4. Enzyme Therapy
  6.3.4.1. Systemic Enzyme Therapy
  6.3.4.2. Digestive Enzyme Therapy
  6.3.5. Thrombolytics
  6.3.5.1. tPA
  6.3.5.2. Streptokinase
  6.3.5.3. Urokinase
  6.3.6. Vaccines
  6.4. Market Attractiveness Analysis, by Drug Type
7. Global Bioengineered Protein Drugs Market Analysis and Forecast, by Disease Condition
  7.1. Introduction & Definition
  7.2. Key Findings/Developments
  7.3. Market Value Forecast, by Disease Condition, 2020-2034
  7.3.1. Cancer
  7.3.2. Diabetes
  7.3.3. Autoimmune Disorder
  7.3.4. Infectious Disease
  7.3.5. Hematopoiesis
  7.3.6. CVD
  7.3.7. Neurodegenerative
  7.3.8. Others
  7.4. Market Attractiveness Analysis, by Disease Condition
8. Global Bioengineered Protein Drugs Market Analysis and Forecast, by End-user
  8.1. Introduction & Definition
  8.2. Key Findings/Developments
  8.3. Market Value Forecast, by End-user, 2020-2034
  8.3.1. Pharma and Biotech Companies
  8.3.2. CROs
  8.3.3. Research Institutes
  8.4. Market Attractiveness Analysis, by End-user
9. Global Bioengineered Protein Drugs Market Analysis and Forecast, by Region
  9.1. Key Findings
  9.2. Market Value Forecast, by Region, 2020-2034
  9.2.1. North America
  9.2.2. Europe
  9.2.3. Asia Pacific
  9.2.4. Latin America
  9.2.5. Middle East & Africa
  9.3. Market Attractiveness Analysis, by Region
10. North America Bioengineered Protein Drugs Market Analysis and Forecast
  10.1. Introduction
  10.2. Key Findings
  10.3. Market Value Forecast, by Drug Type, 2020-2034
  10.3.1. Monoclonal Antibodies
  10.3.1.1. Humira
  10.3.1.2. Rituxan
  10.3.1.3. Avastin
  10.3.1.4. Herceptin
  10.3.1.5. Remicade
  10.3.1.6. Lucentis
  10.3.1.7. Enbrel
  10.3.1.8. Synazis
  10.3.1.9. Others
  10.3.2. Therapeutic Proteins
  10.3.2.1. Hormones
  10.3.2.2. Cytokines
  10.3.2.2.1. Neupogen
  10.3.2.2.2. Neulasta
  10.3.2.2.3. Interferon Alpha
  10.3.2.2.4. Erythropoietin Alpha
  10.3.2.2.5. Interleukin
  10.3.2.2.6. Others
  10.3.3. Blood Factor
  10.3.4. Enzyme Therapy
  10.3.4.1. Systemic Enzyme Therapy
  10.3.4.2. Digestive Enzyme Therapy
  10.3.5. Thrombolytics
  10.3.5.1. tPA
  10.3.5.2. Streptokinase
  10.3.5.3. Urokinase
  10.3.6. Vaccines
  10.4. Market Value Forecast, by Disease Condition, 2020-2034
  10.4.1. Cancer
  10.4.2. Diabetes
  10.4.3. Autoimmune Disorder
  10.4.4. Infectious Disease
  10.4.5. Hematopoiesis
  10.4.6. CVD
  10.4.7. Neurodegenerative
  10.4.8. Others
  10.5. Market Value Forecast, by End-user, 2020-2034
  10.5.1. Pharma and Biotech Companies
  10.5.2. CROs
  10.5.3. Research Institutes
  10.6. Market Value Forecast, by Country, 2020-2034
  10.6.1. U.S.
  10.6.2. Canada
  10.7. Market Attractiveness Analysis
  10.7.1. By Drug Type
  10.7.2. By Disease Condition
  10.7.3. By End-user
  10.7.4. By Country
11. Europe Bioengineered Protein Drugs Market Analysis and Forecast
  11.1. Introduction
  11.2. Key Findings
  11.3. Market Value Forecast, by Drug Type, 2020-2034
  11.3.1. Monoclonal Antibodies
  11.3.1.1. Humira
  11.3.1.2. Rituxan
  11.3.1.3. Avastin
  11.3.1.4. Herceptin
  11.3.1.5. Remicade
  11.3.1.6. Lucentis
  11.3.1.7. Enbrel
  11.3.1.8. Synazis
  11.3.1.9. Others
  11.3.2. Therapeutic Proteins
  11.3.2.1. Hormones
  11.3.2.2. Cytokines
  11.3.2.2.1. Neupogen
  11.3.2.2.2. Neulasta
  11.3.2.2.3. Interferon Alpha
  11.3.2.2.4. Erythropoietin Alpha
  11.3.2.2.5. Interleukin
  11.3.2.2.6. Others
  11.3.3. Blood Factor
  11.3.4. Enzyme Therapy
  11.3.4.1. Systemic Enzyme Therapy
  11.3.4.2. Digestive Enzyme Therapy
  11.3.5. Thrombolytics
  11.3.5.1. tPA
  11.3.5.2. Streptokinase
  11.3.5.3. Urokinase
  11.3.6. Vaccines
  11.4. Market Value Forecast, by Disease Condition, 2020-2034
  11.4.1. Cancer
  11.4.2. Diabetes
  11.4.3. Autoimmune Disorder
  11.4.4. Infectious Disease
  11.4.5. Hematopoiesis
  11.4.6. CVD
  11.4.7. Neurodegenerative
  11.4.8. Others
  11.5. Market Value Forecast, by End-user, 2020-2034
  11.5.1. Pharma and Biotech Companies
  11.5.2. CROs
  11.5.3. Research Institutes
  11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
  11.6.1. Germany
  11.6.2. U.K.
  11.6.3. France
  11.6.4. Italy
  11.6.5. Spain
  11.6.6. Rest of Europe
  11.7. Market Attractiveness Analysis
  11.7.1. By Drug Type
  11.7.2. By Disease Condition
  11.7.3. By End-user
  11.7.4. By Country/Sub-region
12. Asia Pacific Bioengineered Protein Drugs Market Analysis and Forecast
  12.1. Introduction
  12.2. Key Findings
  12.3. Market Value Forecast, by Drug Type, 2020-2034
  12.3.1. Monoclonal Antibodies
  12.3.1.1. Humira
  12.3.1.2. Rituxan
  12.3.1.3. Avastin
  12.3.1.4. Herceptin
  12.3.1.5. Remicade
  12.3.1.6. Lucentis
  12.3.1.7. Enbrel
  12.3.1.8. Synazis
  12.3.1.9. Others
  12.3.2. Therapeutic Proteins
  12.3.2.1. Hormones
  12.3.2.2. Cytokines
  12.3.2.2.1. Neupogen
  12.3.2.2.2. Neulasta
  12.3.2.2.3. Interferon Alpha
  12.3.2.2.4. Erythropoietin Alpha
  12.3.2.2.5. Interleukin
  12.3.2.2.6. Others
  12.3.3. Blood Factor
  12.3.4. Enzyme Therapy
  12.3.4.1. Systemic Enzyme Therapy
  12.3.4.2. Digestive Enzyme Therapy
  12.3.5. Thrombolytics
  12.3.5.1. tPA
  12.3.5.2. Streptokinase
  12.3.5.3. Urokinase
  12.3.6. Vaccines
  12.4. Market Value Forecast, by Disease Condition, 2020-2034
  12.4.1. Cancer
  12.4.2. Diabetes
  12.4.3. Autoimmune Disorder
  12.4.4. Infectious Disease
  12.4.5. Hematopoiesis
  12.4.6. CVD
  12.4.7. Neurodegenerative
  12.4.8. Others
  12.5. Market Value Forecast, by End-user, 2020-2034
  12.5.1. Pharma and Biotech Companies
  12.5.2. CROs
  12.5.3. Research Institutes
  12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
  12.6.1. China
  12.6.2. Japan
  12.6.3. India
  12.6.4. Australia & New Zealand
  12.6.5. Rest of Asia Pacific
  12.7. Market Attractiveness Analysis
  12.7.1. By Drug Type
  12.7.2. By Disease Condition
  12.7.3. By End-user
  12.7.4. By Country/Sub-region
13. Latin America Bioengineered Protein Drugs Market Analysis and Forecast
  13.1. Introduction
  13.2. Key Findings
  13.3. Market Value Forecast, by Drug Type, 2020-2034
  13.3.1. Monoclonal Antibodies
  13.3.1.1. Humira
  13.3.1.2. Rituxan
  13.3.1.3. Avastin
  13.3.1.4. Herceptin
  13.3.1.5. Remicade
  13.3.1.6. Lucentis
  13.3.1.7. Enbrel
  13.3.1.8. Synazis
  13.3.1.9. Others
  13.3.2. Therapeutic Proteins
  13.3.2.1. Hormones
  13.3.2.2. Cytokines
  13.3.2.2.1. Neupogen
  13.3.2.2.2. Neulasta
  13.3.2.2.3. Interferon Alpha
  13.3.2.2.4. Erythropoietin Alpha
  13.3.2.2.5. Interleukin
  13.3.2.2.6. Others
  13.3.3. Blood Factor
  13.3.4. Enzyme Therapy
  13.3.4.1. Systemic Enzyme Therapy
  13.3.4.2. Digestive Enzyme Therapy
  13.3.5. Thrombolytics
  13.3.5.1. tPA
  13.3.5.2. Streptokinase
  13.3.5.3. Urokinase
  13.3.6. Vaccines
  13.4. Market Value Forecast, by Disease Condition, 2020-2034
  13.4.1. Cancer
  13.4.2. Diabetes
  13.4.3. Autoimmune Disorder
  13.4.4. Infectious Disease
  13.4.5. Hematopoiesis
  13.4.6. CVD
  13.4.7. Neurodegenerative
  13.4.8. Others
  13.5. Market Value Forecast, by End-user, 2020-2034
  13.5.1. Pharma and Biotech Companies
  13.5.2. CROs
  13.5.3. Research Institutes
  13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
  13.6.1. Brazil
  13.6.2. Mexico
  13.6.3. Rest of Latin America
  13.7. Market Attractiveness Analysis
  13.7.1. By Drug Type
  13.7.2. By Disease Condition
  13.7.3. By End-user
  13.7.4. By Country/Sub-region
14. Middle East & Africa Bioengineered Protein Drugs Market Analysis and Forecast
  14.1. Introduction
  14.2. Key Findings
  14.3. Market Value Forecast, by Drug Type, 2020-2034
  14.3.1. Monoclonal Antibodies
  14.3.1.1. Humira
  14.3.1.2. Rituxan
  14.3.1.3. Avastin
  14.3.1.4. Herceptin
  14.3.1.5. Remicade
  14.3.1.6. Lucentis
  14.3.1.7. Enbrel
  14.3.1.8. Synazis
  14.3.1.9. Others
  14.3.2. Therapeutic Proteins
  14.3.2.1. Hormones
  14.3.2.2. Cytokines
  14.3.2.2.1. Neupogen
  14.3.2.2.2. Neulasta
  14.3.2.2.3. Interferon Alpha
  14.3.2.2.4. Erythropoietin Alpha
  14.3.2.2.5. Interleukin
  14.3.2.2.6. Others
  14.3.3. Blood Factor
  14.3.4. Enzyme Therapy
  14.3.4.1. Systemic Enzyme Therapy
  14.3.4.2. Digestive Enzyme Therapy
  14.3.5. Thrombolytics
  14.3.5.1. tPA
  14.3.5.2. Streptokinase
  14.3.5.3. Urokinase
  14.3.6. Vaccines
  14.4. Market Value Forecast, by Disease Condition, 2020-2034
  14.4.1. Cancer
  14.4.2. Diabetes
  14.4.3. Autoimmune Disorder
  14.4.4. Infectious Disease
  14.4.5. Hematopoiesis
  14.4.6. CVD
  14.4.7. Neurodegenerative
  14.4.8. Others
  14.5. Market Value Forecast, by End-user, 2020-2034
  14.5.1. Pharma and Biotech Companies
  14.5.2. CROs
  14.5.3. Research Institutes
  14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
  14.6.1. GCC Countries
  14.6.2. South Africa
  14.6.3. Rest of Middle East & Africa
  14.7. Market Attractiveness Analysis
  14.7.1. By Drug Type
  14.7.2. By Disease Condition
  14.7.3. By End-user
  14.7.4. By Country/Sub-region
15. Competition Landscape
  15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  15.2. Market Share Analysis, by Company (2023)
  15.3. Company Profiles
  15.3.1. Abbott
  15.3.1.1. Company Overview
  15.3.1.2. Product Portfolio
  15.3.1.3. SWOT Analysis
  15.3.1.4. Financial Overview
  15.3.1.5. Strategic Overview
  15.3.2. Amgen Inc.
  15.3.2.1. Company Overview
  15.3.2.2. Product Portfolio
  15.3.2.3. SWOT Analysis
  15.3.2.4. Financial Overview
  15.3.2.5. Strategic Overview
  15.3.3. Bayer AG
  15.3.3.1. Company Overview
  15.3.3.2. Product Portfolio
  15.3.3.3. SWOT Analysis
  15.3.3.4. Financial Overview
  15.3.3.5. Strategic Overview
  15.3.4. Biocon
  15.3.4.1. Company Overview
  15.3.4.2. Product Portfolio
  15.3.4.3. SWOT Analysis
  15.3.4.4. Financial Overview
  15.3.4.5. Strategic Overview
  15.3.5. Dr. Reddy's Laboratories
  15.3.5.1. Company Overview
  15.3.5.2. Product Portfolio
  15.3.5.3. SWOT Analysis
  15.3.5.4. Financial Overview
  15.3.5.5. Strategic Overview
  15.3.6. Lilly
  15.3.6.1. Company Overview
  15.3.6.2. Product Portfolio
  15.3.6.3. SWOT Analysis
  15.3.6.4. Financial Overview
  15.3.6.5. Strategic Overview
  15.3.7. F. Hoffmann - La Roche Ltd.
  15.3.7.1. Company Overview
  15.3.7.2. Product Portfolio
  15.3.7.3. SWOT Analysis
  15.3.7.4. Financial Overview
  15.3.7.5. Strategic Overview
  15.3.8. Fresenius Kabi AG
  15.3.8.1. Company Overview
  15.3.8.2. Product Portfolio
  15.3.8.3. SWOT Analysis
  15.3.8.4. Financial Overview
  15.3.8.5. Strategic Overview
  15.3.9. GSK
  15.3.9.1. Company Overview
  15.3.9.2. Product Portfolio
  15.3.9.3. SWOT Analysis
  15.3.9.4. Financial Overview
  15.3.9.5. Strategic Overview
  15.3.10. Janssen Global Services
  15.3.10.1. Company Overview
  15.3.10.2. Product Portfolio
  15.3.10.3. SWOT Analysis
  15.3.10.4. Financial Overview
  15.3.10.5. Strategic Overview
  15.3.11. Merck & Co., Inc.
  15.3.11.1. Company Overview
  15.3.11.2. Product Portfolio
  15.3.11.3. SWOT Analysis
  15.3.11.4. Financial Overview
  15.3.11.5. Strategic Overview
  15.3.12. Novartis AG
  15.3.12.1. Company Overview
  15.3.12.2. Product Portfolio
  15.3.12.3. SWOT Analysis
  15.3.12.4. Financial Overview
  15.3.12.5. Strategic Overview
  15.3.13. Panacea Biotec
  15.3.13.1. Company Overview
  15.3.13.2. Product Portfolio
  15.3.13.3. SWOT Analysis
  15.3.13.4. Financial Overview
  15.3.13.5. Strategic Overview
  15.3.14. ProBioGen AG
  15.3.14.1. Company Overview
  15.3.14.2. Product Portfolio
  15.3.14.3. SWOT Analysis
  15.3.14.4. Financial Overview
  15.3.14.5. Strategic Overview
  15.3.15. Reliance Life Science
  15.3.15.1. Company Overview
  15.3.15.2. Product Portfolio
  15.3.15.3. SWOT Analysis
  15.3.15.4. Financial Overview
  15.3.15.5. Strategic Overview
  15.3.16. Sanofi
  15.3.16.1. Company Overview
  15.3.16.2. Product Portfolio
  15.3.16.3. SWOT Analysis
  15.3.16.4. Financial Overview
  15.3.16.5. Strategic Overview

$5,795
$8,795
$11,795

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings